Iniparib May Be Effective as Salvage Therapy for Metastatic Triple-Negative Breast ​Cancer

Share this content:
Iniparib plus gemcitabine and carboplatin did not meet criteria for the primary endpoints of survival.
Iniparib plus gemcitabine and carboplatin did not meet criteria for the primary endpoints of survival.

According to a new study published online ahead of print in the Journal of Clinical Oncology, researchers have found that iniparib plus gemcitabine and carboplatin did not meet prespecified criteria for the primary endpoints of progression-free survival and overall survival in patients with metastatic triple-negative breast cancer.

For this phase 3, multicenter, open-label study, researchers randomly assigned 519 women with stage 4 or locally recurrent triple-negative breast cancer to receive gemcitabine plus carboplatin or the same chemotherapy regimen in addition to iniparib.

Of the patients that received the three-drug combination, 65% were 50 years of age or older, 98% had an Eastern Cooperative Oncology Group performance status of 0 or 1, 89% had received prior chemotherapy, and 57% were receiving this treatment as first-line therapy.

Patients received gemcitabine 1,000 mg/m2 and carboplatin area under the curve 2 on days 1 and 8, and patients in the three-drug group also received iniparib 5.6 mg/kg on days 1, 4, 8, and 11. Cycles were repeated every 3 weeks.1

Results showed no statistically significant difference for overall survival (hazard ratio [HR]=0.88; 95% confidence interval [CI], 0.69, 1.12; P =0.28) or progression-free survival (HR=0.79; 95% CI, 0.65,0.98; P=0.98) between both groups.

RELATED: Breast Cancer (Recurrent or Metastatic) Treatment Regimens

The researchers performed an exploratory analysis and found that patients receiving iniparib plus gemcitabine and carboplatin had improved overall survival (HR=0.65; 95% CI, 0.46,0.91) or progression-free survival (HR=0.68; 95% CI, 0.50,0.92) compared with those who received gemcitabine and carboplatin only.

The most common adverse effects in both groups were fatigue, nausea, constipation, vomiting, headache, and dyspnea. Incidence rates were similar among both groups.

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs